Brief Correspondence

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma

Jens Bedke\textsuperscript{a,b}, Laurence Albiges\textsuperscript{c}, Umberto Capitanio\textsuperscript{d,e}, Rachel H. Giles\textsuperscript{f}, Milan Hora\textsuperscript{g}, Thomas B. Lam\textsuperscript{h,i}, Börje Ljungberg\textsuperscript{j}, Lorenzo Marconi\textsuperscript{k}, Tobias Klatte\textsuperscript{l}, Alessandro Volpe\textsuperscript{m}, Yasmin Abu-Ghanem\textsuperscript{n}, Saeed Dabestanio\textsuperscript{o}, Sergio Fernández-Pello\textsuperscript{p}, Fabian Hofmann\textsuperscript{q}, Teele Kuusk\textsuperscript{r,s}, Rana Tahbaz\textsuperscript{t}, Thomas Powles\textsuperscript{t}, Axel Bex\textsuperscript{u,v,w,*}

\textsuperscript{a}Department of Urology, University Hospital Tuebingen, Tuebingen, Germany; \textsuperscript{b}German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; \textsuperscript{c}Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France; \textsuperscript{d}Department of Urology, San Raffaele Scientific Institute, Milan, Italy; \textsuperscript{e}Division of Experimental Oncology/Unit of Urology, IRCCS San Raffaele Hospital, Milan, Italy; \textsuperscript{f}International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; \textsuperscript{g}Department of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic; \textsuperscript{h}Academic Urology Unit, University of Aberdeen, Aberdeen, UK; \textsuperscript{i}Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; \textsuperscript{j}Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden; \textsuperscript{k}Department of Urology, Coimbra University Hospital, Coimbra, Portugal; \textsuperscript{l}Department of Urology, Charité – Universitätsmedizin Berlin, Berlin, Germany; \textsuperscript{m}Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy; \textsuperscript{n}Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel; \textsuperscript{o}Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden; \textsuperscript{p}Department of Urology, Cabueñes University Hospital, Gijón, Spain; \textsuperscript{q}Department of Urology, Sunderby Sjukhus, Umeå University, Uleå, Sweden; \textsuperscript{r}Department of Urology, Darent Valley Hospital, Dartford, UK; \textsuperscript{s}Gravesham NHS Trust, Dartford, UK; \textsuperscript{t}The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK; \textsuperscript{u}The Royal Free London NHS Foundation Trust, London, UK; \textsuperscript{v}UCL Division of Surgery and Interventional Science, London, UK; \textsuperscript{w}Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Article info

Article history:
Accepted November 18, 2021

Associate Editor:
James Catto

Keywords:
Adjuvant
Pembrolizumab
Tyrosine kinase inhibitor
High risk
Metastasectomy
Clear cell
Renal cell carcinoma

Abstract

Adjuvant treatment of nonmetastatic high-risk renal cell carcinoma is an unmet medical need. In the past, several tyrosine kinase inhibitor trials have failed to demonstrate an improvement of disease-free survival (DFS) in this setting. Only one trial (S-TRAC) provided evidence for improved DFS with sunitinib but without an overall survival (OS) signal. Keynote-564 is the first trial of an immune checkpoint inhibitor that significantly improved DFS with adjuvant pembrolizumab, a programmed death receptor-1 antibody, in clear cell renal cell carcinoma with a high risk of relapse. The intention-to-treat population, which included a group of patients after metastasectomy and no evidence of disease (M1 NED), had a significant DFS benefit. The OS data are not mature as yet. The Renal Cell Carcinoma Guideline Panel issues a weak recommendation for the adjuvant use of pembrolizumab for high-risk clear cell renal carcinoma, as defined by the trial until final OS data are available. However, the trial reilluminates the discussion on when and in whom metastasectomy should be performed. Here, caution is necessary not to perform metastasectomy in patients with poor prognostic features and rapid progressive disease, which must be excluded by a confirmatory scan of disease status prior to planned metastasectomy.

Patient summary: New data from the adjuvant immune checkpoint inhibitor trial with pembrolizumab (a programmed death receptor-1 antibody) for the treatment of high-risk clear cell renal cell carcinoma (ccRCC) after surgery showed that the drug prolonged
Immune checkpoint inhibitors (ICIs), designed to restore and enhance immune activity against cancer cells, have shown impressive efficacy in advanced renal cell carcinoma (RCC) [1–5]. Several randomised phase III trials of adjuvant ICIs are on-going, and the Keynote-564 trial is the first to report results (Table 1) [6]. A meta-analysis of previous adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy trials has not demonstrated unequivocal disease-free survival (DFS) or overall survival (OS) benefits for patients with high-risk RCC after nephrectomy, and it is neither recommended by the European Association of Urology (EAU) guidelines nor approved by the European Medicines Agency, despite initial enthusiasm [7–9].

### Adjuvant treatment in high-risk RCC

The Keynote-564 phase III trial is the first adjuvant ICI trial to report positive primary endpoint data on DFS [6]. Keynote-564 evaluated pembrolizumab (17 cycles of 3-weekly therapy) versus placebo as adjuvant therapy for 994 patients with intermediate-risk (pT2, grade 4 or sarcomatoid, N0 M0; or pT3, any grade, N0, M0), high-risk (pT4, any grade, N0 M0; or pT any stage, and grade, or N+, M0), or M1 (no evidence of disease [NED] after primary tumour plus soft tissue metastases completely resected ≤1 yr from nephrectomy) disease (Table 2). The median follow-up, defined as the time from randomisation to data cut-off, was 24.1 mo. The primary endpoint of DFS per investigator assessment was significantly improved in the pembrolizumab group versus the placebo group (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.53–0.87, \( p = 0.001 \)). The estimated 24-mo DFS rate was 77% versus 68% for pembrolizumab versus placebo. Benefit occurred across broad subgroups of patients including those with M1/NED disease after surgery (\( n = 58 \% \)). Investigator-assessed DFS was considered preferable to DFS by central review due to its clinical applicability. OS showed a non-statistically significant trend towards a benefit in the pembrolizumab arm (HR 0.54, 95% CI 0.30–0.96, \( p = 0.0164 \)). Follow-up was short and few OS events occurred (2-yr OS rate of 97% [pembrolizumab] vs 94% [placebo]). Grade 3–5 all-cause adverse events occurred in 32% versus 18% of patients for pembrolizumab versus placebo. Quality of life assessment by FKSI-DRS and QLQ30 did not show a statistically significant or clinically meaningful deterioration in

### Table 1 – Updated EAU RCC guideline recommendation for the adjuvant treatment of high-risk ccRCC

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Experimental arm</th>
<th>Primary endpoint</th>
<th>Risk groups</th>
<th>DFS (mo) Median (95% CI)</th>
<th>OS (mo) Median (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keynote-564</td>
<td>994</td>
<td>Pembrolizumab 200 mg IV Q3W (17 cycles) vs placebo</td>
<td>DFS in the ITT by IR</td>
<td>Intermediate-high: pT2 grade 4 or sarcomatoid; pT3 any grade</td>
<td>ITT: Pembro: NR (NE) Placebo: NR (NE)</td>
<td>ITT: Pembro: NR (NE) Placebo: NR (NE)</td>
</tr>
<tr>
<td>NCT03142334</td>
<td></td>
<td></td>
<td></td>
<td>High: pT4 any grade, pN1</td>
<td>HR: 0.68 (95% CI: 0.53–0.87) P &lt; 0.002 Not significant</td>
<td>HR: 0.54 (95% CI: 0.30–0.96)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M1 NED: cM0 after resection of oligometastatic disease &lt;12 mo</td>
<td>DFS at 24 mo: Pembro: 77.3% Placebo: 68.1%</td>
<td>Alive at 24 mo: Pembro: 96.6% Placebo: 93.5%</td>
</tr>
</tbody>
</table>

CI = confidence interval; HR = hazard ratio; IR = investigator review; ITT = intention-to-treat; IV = intravenous; mo = months; NE = non-estimable; NR = not reached; OS = overall survival; PD-1 = programmed death-receptor 1; PEMBRO = pembrolizumab; PFS = progression-free survival; Q3W = every 3 weeks.

---

the period of being cancer free significantly, although whether it prolonged survival remained uncertain. Consequently, pembrolizumab is cautiously recommended as additional (ie, adjuvant) treatment in high-risk ccRCC after kidney cancer surgery.

© 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
health-related quality of life or symptom scores for either adjuvant pembrolizumab or placebo.

After quality of evidence and strength of recommendation assessment using a modified GRADE approach, the EAU RCC Guideline Panel reached consensus and issued a weak recommendation for adjuvant pembrolizumab for patients with high-risk (defined as per study) operable clear-cell renal cell cancer (ccRCC; Supplementary material), at least until the final OS data are available. The panel included a patient questionnaire and a poll among their guideline members prior to Kyenote-564 data release in their assessment of the harms and benefits (Supplementary material). Although the EAU guideline previously did not recommend sunitinib despite positive DFS data in the absence of OS benefit [10–12], the panel decided to recommend adjuvant pembrolizumab for the following reasons:

1. ICI therapy has a different mode of action than VEGFR tyrosine kinase inhibitor (TKI), resulting in complete responses in up to 16% of patients in programmed death receptor-1 (PD-1) unselected populations in metastatic disease [3].
2. Despite immature OS data with the early OS signal potentially driven by the M1 population, the panel cannot exclude that a survival benefit will emerge. This was not the case in the adjuvant sunitinib trial (STRAC) [6,12].
3. Pembrolizumab is better tolerated than sunitinib and does not lead to a decline of quality of life compared with placebo, unlike sunitinib [6,13].
4. A number of adjuvant VEGFR trials failed to show a DFS advantage for sunitinib or other VEGFR inhibitors, resulting in a negative meta-analysis [9].

The panel considered the following cautionary points in their decision, which led to a weak recommendation:

1. A high proportion of patients, cured by surgery, are receiving unnecessary and potentially harmful treatment.
2. The tolerability profile is acceptable, but grade 3–5 adverse events were 14.7% higher in the pembrolizumab arm (32.4%) than in the placebo arm (17.7%, all cause). Approximately 18% of patients required treatment discontinuation early for adverse events, which provides a broad indicator of tolerability. Endocrine adverse events may require lifelong therapy.
3. Other ICI trials have not yet been reported and are not available for meta-analysis.
4. Biomarker analyses to predict outcome and adverse events are not available.
5. Final OS data are not yet available.

**Metastasectomy and subsequent systemic treatment in M1 NED**

The panel acknowledges that the trial needs to be assessed based on its original design, which includes a small percentage of patients who underwent complete metastasectomy (6% in the experimental arm and 6% in the placebo arm). However, in Kyenote-564, patients in the M1 NED cohort had metastasectomy within 1 yr after primary diagnosis. A metachronous interval of <1 yr for recurrences following surgery with curative intent is a poor prognostic factor [14]. Systemic therapy based on immune combinations has stronger levels of evidence than surgery in this advanced disease setting [15]. In addition, TKI-driven adjuvant trials after metastasectomy have shown no DFS or OS benefit [16,17].

Results for single-agent pembrolizumab after surgery for metastatic disease are therefore difficult to interpret due to the small subgroup. Nevertheless, the DFS HR of 0.29 (95% CI 0.12–0.69) in favour of resection of M1 to NED plus pembrolizumab shows that patients with subclinical but progressive disease who were subjected to metastasectomy had a benefit of adjuvant systemic therapy with pembrolizumab. Based on the current data, it cannot be concluded that for patients with oligoprogressive disease, metastasectomy within the 1st year of initial diagnosis of the primary and subsequent adjuvant pembrolizumab is superior to a period of observation and dual immunotherapy-based combination first-line therapy upon progression. Data from the TKI era suggest that patients with metastatic disease recurrence can be observed for up to a median of 16 mo before systemic therapy is required and that this practice is common in real-world settings (30%) [18,19].

In addition, it is possible that metastasectomy may lead to poorer outcomes compared with systemic therapy approaches as a relapse within the first 12 mo and presentation with synchronous (oligo-) metastatic disease is attributed to the International Metastatic RCC Database Consortium intermediate-risk group [20]. The panel therefore does not encourage metastasectomy and adjuvant pembrolizumab in this advanced population within 1 yr after primary surgery. A careful reassessment of disease status to rule out rapid progressive disease should be performed. Data from other adjuvant ICI studies including M1 NED subgroups may clarify this issue further (IMmotion010, NCT03024996).

**Conclusion**

Keynote-564 is the first trial to demonstrate improved DFS in ccRCC patients in the adjuvant setting. OS is still immature. Further trials with unreported results are currently on-going in this setting (IMmotion010, NCT03024996; CheckMate-914, NCT03138512; RAMPART, NCT03288532; and PROSPER RCC, NCT03055013).

**Author contributions:** Axel Bex had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Bedke, Powles, Ljungberg, Bex.
**Acquisition of data:** Bedke, Bex.
**Analysis and interpretation of data:** Bedke, Powles, Bex.
**Drafting of the manuscript:** Bedke, Bex.
**Critical revision of the manuscript for important intellectual content:** Albiges, Capitanio, Giles, Hora, Lam, Ljungberg, Marconi, Klatte, Volpe, Abu-Ghanem, Dabestani, Fernández-Pello, Hofmann, Kuusk, Tahbaz.
**Statistical analysis:** None.
**Obtaining funding:** None.
**Administrative, technical, or material support:** None.
Supervision: Bedke, Powles, Bex, Ljungberg.
Other: None.

Financial disclosures: Axel Bex certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Professor Dr. J. Bedke has received institutional research funding from AstraZeneca, Astellas, BMS, Eisai, Ipsen, MSD, Novartis, Nektar, Pfizer, Roche, and Seattle Genetics; and received honoraria from BMS and MSD on an institutional basis, and from AstraZeneca, Astellas, BMS, Eisai, EUSA Pharma, Ipsen, MSD, Merck Serono, Novartis, Pfizer, and Roche on a personal basis. Professor Dr. L. Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and received research funding from Pfizer and Novartis. Professor Dr. T. Powles has received institutional research funding from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai; received honoraria from AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai, and Roche on a personal basis; and received travel, accommodation, and other expenses from Roche, Pfizer, MSD, AstraZeneca, and Ipsen. Professor Dr. M. Hora has received company speaker honoraria from Covidiene, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Dr. T.B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Dr. T. Kuusk has received company speaker honorarium and a travel grant from Ipsen. Professor Dr. B. Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. A. Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for BMS, GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. U. Capitanio, Professor Dr. R.H. Giles, Dr. T. Klatt, Professor Dr. A. Volpe, Dr. S. Dabestani, Dr. F. Hofmann, Dr. L. Marconi, Dr. S. Fernández-Pello, Dr. R. Tahbaz, and Dr. Y. Abu-Ghanem have nothing to disclose.

Funding/Support and role of the sponsor: None.

Peer Review Summary

Supplementary data to this article can be found online at https://doi.org/10.1016/j.eururo.2021.11.022.

References


